Skip to content

Adenosine and A2A Receptors in Human Brown Adipose Tissue

Adenosine and A2a Receptors in Human Brown Adipose Tissue (AdenoBAT)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03327168
Acronym
AdenoBAT
Enrollment
11
Registered
2017-10-31
Start date
2015-11-01
Completion date
2016-06-30
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Adipose Tissue, Brown

Brief summary

This study investigates the significance of adenosine and A2A receptors in human brown adipose tissue (BAT) in vivo. Using positron emission tomography (PET), perfusion and the density of A2A receptors will be measured in supraclavicular BAT and other tissues in healthy men. The investigators hypothesize, that adenosine can activate BAT, and that adenosine A2A receptor density changes when BAT is activated by cold exposure. Understanding the mechanisms of BAT activation and the role of endocannabinoids in humans is important and beneficial in fighting against the epidemic of obesity and diabetes.

Detailed description

Adenosine is a purine nucleoside released locally in BAT when noradrenaline and ATP are released from sympathetic nerves. Recently it was found that adenosine activates murine and human brown adipocytes, and recruits beiging of white fat via adenosine A2A receptors (A2AR). Furthermore, studies with mice have shown improvements in glucose homeostasis after administration of A2AR agonists. In this study the investigators use the PET radiotracer \[15O\]-H2O to quantify perfusion of BAT, white adipose tissue (WAT) and muscle in three conditions: room temperature, cold exposure and intravenous infusion of adenosine. Another PET radiotracer \[11C\]TMSX is used to quantify adenosine A2A receptor density of BAT, WAT and muscle in room temperature and during cold exposure.

Interventions

DRUGAdenosine

Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.

OTHERCold exposure

Controlled cold exposure is performed before and during PET/CT scan.

Sponsors

University of Bonn
CollaboratorOTHER
Turku University Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Each subject participates in PET/CT scans in room temperature conditions, during cold exposure and during i.v. infusion of adenosine.

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

1. Male sex 2. BMI 20 - 28 kg/m2 3. Age: 18- 40 years 4. Normal OGTT 5. Healthy, no regular medication

Exclusion criteria

1. BMI \< 20 kg/m2 or BMI \> 28 kg/m2 2. Low or high blood pressure 3. Asthma or other obstructive lung disease 4. Sick sinus syndrome, prolonged QT-interval, or any heart disease 5. Any chronic disease that could affect the study outcome, including diabetes 6. Mental disorder or poor compliance 7. Eating disorder or excessive use of alcohol, tobacco smoking or drug use 8. Past dose of radiation 9. Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results

Design outcomes

Primary

MeasureTime frameDescription
BAT perfusionEffect within 10 minutesPerfusion of BAT with \[15O\]-H2O PET-CT
A2A receptor density in BATEffect within 3 hoursDensity of A2A receptors in BAT measured with \[11C\]-TMSX PET/CT

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026